FEATURED

A 47,000% Call Volume Surge in One Name

The Signal

Most unusual options activity is noise. Volume spikes a few hundred percent above average. A big block crosses, probably a roll or a hedge. You log it, move on.

Today is different.

First Advantage Corporation (NYSE: FA) saw call options volume run at over 1,000 times its daily average on Monday, July 14. The number that surfaced across multiple flow trackers: 6,131 call contracts traded on a single strike, the July 17 $22.50 call, against open interest of zero. Every contract was a fresh position. The average daily call volume in this name is approximately 13 contracts. Traders bought 6,131. That is a relative volume increase of roughly 47,000% in one session.

When open interest reads zero and volume reads 6,131, there is no ambiguity about what happened. Someone opened a significant new position, at the ask, expiring in three days, targeting a strike roughly 8% above where the stock was trading that morning.

The question worth asking is not whether this is notable. It clearly is. The question is why.

Why It Matters

Short-dated, out-of-the-money call buying expiring in three days is not a hedge. Nobody hedges a long position with a call that expires Friday. That structure is directional speculation, period. Whoever placed this trade is expressing a view that FA moves significantly higher in the next 72 hours, or they have reason to believe something specific happens before Friday’s close.

The sweep-versus-block distinction matters here. The Schwab options desk flagged this activity Monday morning, and the volume concentration on a single strike with zero prior open interest points to a high-urgency, high-conviction entry rather than a spread leg or a rolling strategy. Sweep orders indicate urgency that retail flow rarely generates at this size. This is someone who needed to be in the position immediately.

What are they expecting? The $22.50 strike implies the trader needs FA to move from roughly $20.77 at the time of the trade to above $22.50, and do it by Friday. That is an implied move of about 8.3% in three sessions. For a background screening company that until recently was trading near its 52-week low, that is not a casual bet.

The Company Behind the Signal

First Advantage is a global software and data company operating primarily in the HR technology space. Its core business is employment background screening and identity verification. In October 2024, the company completed its $2.2 billion acquisition of Sterling Check Corp., which made it the largest background screening company in the world by volume, running over 100 million screens per year across more than 200 countries.

The post-merger integration story has been executing well. First Quarter 2026 results, reported May 7, showed revenues of $385.2 million, representing 8.6% year-over-year growth. Adjusted EBITDA came in at $105.3 million, a 27.3% margin. Adjusted diluted EPS was $0.26, beating the consensus estimate of $0.21 by $0.05. The company reaffirmed full-year 2026 guidance of $1.625 billion to $1.700 billion in revenue, with adjusted diluted EPS guidance of $1.15 to $1.25.

The stock has been on a meaningful run from its 52-week low of $8.82. As of Monday, shares were trading around $20.77, just off a 52-week high of $20.97. The 50-day moving average sits at approximately $16.44, and the 200-day is around $13.84. The stock has more than doubled from its lows in roughly twelve months.

Several structural catalysts have contributed to that run:

• In June 2026, FA was added to the S&P SmallCap 600 and S&P 1000 indices, replacing Kennedy-Wilson. Index inclusion creates structural buying from passive funds and puts the name on more institutional radar screens.
• In Q1 2026, the company completed $50 million in voluntary debt prepayments and repurchased $19.5 million in shares under a newly authorized $100 million buyback program. That combination signals management confidence in free cash flow durability.
• JPMorgan raised its price target to $18.00 with an Overweight rating in May 2026. Stifel Nicolaus matched at $18.00. Both calls came after the Q1 beat.
• The successful Sterling integration has expanded FA’s global reach and AI-driven identity verification capabilities, which are becoming competitive differentiators in a market increasingly focused on digital compliance.

And yet, here is the part worth sitting with: shares are pressing against a 52-week high right now. The 50-day and 200-day moving averages are well below current levels. The stock has already reflected much of the fundamental improvement. A call buyer targeting $22.50 by Friday is not expressing a view about 2026 guidance. They are positioning for something more immediate.

Q2 2026 earnings are the likely candidate. The company reported Q1 on May 7, placing the Q2 report in early August. But conference activity, preliminary data, or any pre-announcement could surface before then. The broader macro backdrop adds one more layer: background screening volume is a direct proxy for employment activity. In an environment where labor market data remains closely watched, any signal about hiring trends could move this stock.

What the Market Is Pricing In

The July 17 $22.50 call purchased at the ask on Monday implies at minimum an 8.3% move to breakeven by expiration. Given the three-day window, that is a compressed expected move relative to any reasonable historical baseline for this stock.

A few things stand out about that positioning:

• The $22.50 strike is above the 52-week high of $20.97. The buyer is targeting price discovery, not a retest of resistance.
• The zero open interest at this strike before Monday means no prior participants had this view at this level. This is new conviction, not accumulated positioning.
• The size, 6,131 contracts representing roughly 613,000 shares of notional exposure, is meaningful relative to the company’s average daily share volume of approximately 1.3 million shares.
• The premium paid was absorbed at the ask, suggesting urgency and price insensitivity consistent with informed flow rather than algorithmic or retail activity.

What is the market pricing in? In short: a sharp, near-term catalyst. The specific trigger is unknown from the outside, but the structure of the trade does not allow for a slow drift higher. This is a binary bet on something happening fast.

Slight tangent, but it matters: background screening companies are often early-read indicators on the hiring cycle. When volumes accelerate, it means companies are onboarding people. When they contract, you feel it before the payroll numbers catch up. If FA is seeing accelerating screen volume in Q2, and management knows it, that would explain both the stock strength and the options urgency.

Strategic Considerations

Before discussing any structure, the honest framing is this: three-day options are not investment vehicles. They are speculation on a specific short-term outcome. Buying the July 17 $22.50 call outright at this point, with the trade already in the market and premium elevated, means paying for implied move that has already been partially acknowledged by the market. That is a different risk profile than the original entry.

For traders who believe the catalyst thesis has merit but want a defined-risk structure with more time:

Bull Case

If you believe a near-term positive development is likely, a call debit spread targeting the August expiration gives directional exposure with defined risk and reduced premium cost relative to a naked long call. For example, a structure buying the August $21 call and selling the August $24 call defines maximum loss to the net debit paid while capping the gain at the spread width minus the premium. This approach removes the urgency mismatch of a three-day expiration while keeping the directional thesis intact. Implied volatility elevation on the front-week calls makes buying further-dated options relatively less expensive by comparison.

Bear Case

The counterargument is straightforward. FA is trading at or near its 52-week high. The stock has more than doubled from its lows. The options flow could represent a speculative bet that does not play out. A position that bets on a reversal from these levels, structured as a put debit spread in the August expiration below current support, reflects the view that the extraordinary call buying does not precede a move and instead represents the exhaustion of near-term buying interest. For traders expecting a fade, a defined-risk put spread limits exposure to the net debit paid.

Neutral Case

If the view is that the stock moves but the direction is uncertain, the elevated short-term implied volatility creates an opportunity to sell premium further out. A short iron condor in the August expiration, positioned outside the expected move range, collects credit if the stock remains within a defined band through expiration. The risk is assignment if the stock breaks one of the short strikes. This structure suits traders who believe the options market is currently overpricing the probability of an extreme move.

A Secondary Signal Worth Watching: SELLAS Life Sciences (SLS)

While FA dominated the flow story today, a second name generated attention: SELLAS Life Sciences (NASDAQ: SLS), a late-stage oncology biotech focused on acute myeloid leukemia.

The options signal: roughly 7:1 calls over puts, driven primarily by a 20,000-contract block purchased on the January 2027 $15.00 call at the ask price of $6.50. Open interest on that contract stood at 12,073 before the trade, which confirms this represents fresh directional positioning. Buying at the ask with a block of this size signals bullish intent.

The reason this name commands attention is the pipeline clock. As of May 11, 2026, SELLAS reported that 78 of the required 80 events have occurred in the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in AML patients who achieved complete remission after second-line salvage therapy. The 80th event triggers a database lock, blinded data review, statistical analysis, unblinding, and topline disclosure. The company has stated it will announce when the 80th event is reached.

Two events away. That is not a vague horizon. That is imminent.

The January 2027 expiration on the call block gives the buyer roughly six months of runway to capture a positive REGAL readout and any subsequent regulatory or partnership activity. SLS009, the company’s CDK9 inhibitor, showed a 46% overall response rate in relapsed/refractory AML at ASH 2025, with topline data from the newly-diagnosed Phase 2 study expected in Q4 2026. The company held $107.1 million in cash as of Q1 2026, providing operational runway. Phase 2 SLS009 data from the Phase 2 trial in newly diagnosed AML is expected in Q4 2026.

The risk here is exactly what you would expect with a binary biotech catalyst. If REGAL fails, the stock declines sharply. That is the nature of event-driven options positioning in small-cap oncology. The January 2027 expiration suggests the buyer is not expecting the readout tomorrow, but is positioning for a series of catalysts between now and year-end. The call block at $6.50 premium, purchased on an $12.51 stock, requires significant appreciation to be profitable.

For traders evaluating the SLS signal, the key structural question is whether to use a defined-risk approach. A bull call spread using January 2027 expirations, buying a lower strike and selling a higher strike, reduces premium outlay while maintaining directional exposure. It also limits the upside, which in a binary biotech readout situation may or may not be an acceptable tradeoff depending on one’s conviction and position sizing discipline.

What to Watch

For FA specifically, the checklist between now and Friday expiration:

• Any pre-announcement, preliminary revenue disclosure, or investor conference appearance that touches Q2 performance or volume trends.
• Whether Friday’s expiration passes without a catalyst, which would likely result in the $22.50 calls expiring worthless and creating downward pressure on the stock as implied volatility reverts.
• Whether additional unusual call volume surfaces in subsequent sessions, which would suggest the original flow was either correct or attracting sympathy positioning.
• Broader labor market data and employment sector commentary, given FA’s business is directly tied to hiring volumes.

For SLS, the watch item is simpler and binary: the announcement of the 80th REGAL event. When it arrives, the formal readout sequence begins. That is the only clinical event that matters for the near-term thesis, and the January 2027 call block suggests someone is already positioned for it.

Risk Assessment

The principal risk for anyone following the FA call flow is overfitting to a single day’s signal without a catalyst to anchor the thesis. Unusual options activity explains positioning. It does not guarantee outcomes. An estimated 30% to 40% of flagged unusual activity represents hedging, spread legs, or roll positions rather than informed directional bets, according to Cboe research. This trade does not look like a hedge or a roll given the zero open interest and single-strike concentration. But the absence of a confirmed catalyst means the thesis rests on inference rather than fact.

The risk for SLS is the binary nature of clinical outcomes. REGAL could be positive or negative. The options market is expressing bullish positioning, but the trial is blinded and SELLAS itself does not know the outcome until unblinding occurs after the 80th event. Any defined-risk structure in SLS should be sized accordingly, with the understanding that a negative readout would likely result in a complete loss of premium paid.

In both cases, the options market is doing exactly what it is designed to do: expressing probabilistic views about future outcomes before those outcomes are known. That is the information worth extracting from today’s flow. Not a prediction, not a trade recommendation, but a directional read on where sophisticated participants are placing their bets and why the structure of those bets deserves attention.

The options market knew something before the stock did. It usually does.

Tactical Checklist

• FA July 17 $22.50 call: 6,131 contracts traded vs. 0 open interest. Volume is 47,000%+ above average daily volume of 13 calls. Treat as a high-urgency directional bet requiring a confirmed catalyst to act on with confidence.
• FA fundamentals: Q1 2026 revenue $385.2M (up 8.6% YoY), adjusted EPS $0.26 vs. $0.21 consensus. Full-year guidance: $1.625B-$1.700B revenue, $1.15-$1.25 adjusted EPS. Execution is solid.
• FA technical: Stock near 52-week high of $20.97. 50-day MA at $16.44, 200-day at $13.84. Momentum is extended. Any catalyst failure near this level risks a sharp reversal.
• FA defined-risk consideration: An August call debit spread allows directional exposure with defined maximum loss if the catalyst thesis proves wrong or premature.
• SLS January 2027 $15 call block: 20,000 contracts at ask, fresh positioning. Catalyst: Phase 3 REGAL 80th event expected imminently (78 of 80 events recorded as of May 11, 2026).
• SLS risk framework: Binary clinical event. A defined-risk call spread in January 2027 expiration reduces premium exposure while maintaining upside participation if REGAL reads positive.
• Both names require independent verification of any catalyst before acting. Unusual flow informs attention allocation. It does not replace due diligence.

Options Trading Report